RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--The data most often requested of drug manufacturers by healthcare payers, and those they find to be the most effective, are comparative effectiveness data and budget impact models.
According to surveyed HOL teams in a Cutting Edge Information’s report, “Advanced Health Outcomes Liaison and Managed Care Liaison Teams: Delivering Health Economics and Clinical Data To Payers,” the two questions payers ask when evaluating a drug are:
1. Is this drug more effective than the competitors?
2. How will it affect our budget?
Clinical trial results fall to the bottom of HOLs’ priority lists because payers are not as interested in efficacy results that come from such a sterile clinical environment. Payers prefer comparative data, such as head-to-head studies, and real-world use data over clinical trial results.
The report details payers’ needs and how HOL teams are structured to meet them. It also found that in countries with single-payer systems, such as Canada and the United Kingdom, payers differ in their product data preference. Cost-effectiveness assessments are most impactful when speaking with Canadian and UK payers.
This preference points to Canadian and UK payers’ emphasis on drug cost, not just efficacy. “In an effort to contain costs and be able to provide universal healthcare, prescription costs — including long-term costs linked to different health outcomes — must be key factors in any reimbursement decision,” said Nicole May, research analyst at Cutting Edge Information. In both cases, with the exception of an interviewed US biologic company, clinical trial results ranked last on these payers’ lists of data preferences.
The study “Advanced Health Outcomes Liaison and Managed Care Liaison Teams: Delivering Health Economics and Clinical Data To Payers,” available at (http://www.cuttingedgeinfo.com/research/medical-affairs/health-outcomes-liaisons/), includes staffing and budget metrics to help companies build their HOL and MCL functions. Health economics teams and medical affairs executives can use this report to:
- Determine ideal HOL team structures and reporting lines to effectively support both US and ex-US payers’ needs.
- Understand what data and tools HOL and MCL teams find most effective when speaking with payers.
- Compare how other companies are planning, developing and sizing their liaison teams and territories.
For more information about health outcomes liaison management, contact Cassie Demeter at 919-403-6583.
